The CATIE study [15]

American Journal of Psychiatry

Volumn 163, Issue 3, 2006, Pages 554-555

  Teich, Jeffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; OLANZAPINE; PERPHENAZINE; QUETIAPINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETICS; HUMAN; LETTER; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHIATRIST; SCHIZOPHRENIA; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TREATMENT WITHDRAWAL; CHRONIC DISEASE; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; METHODOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTICENTER STUDIES; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 33645903204     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.163.3.554     Document Type: Letter

References (24)

1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Clinical Antipsychotic Trials of Intervention Effectiveness [CATIE] Investigators): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
2. Bagnall A, Lewis RA, Leitner ML: Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; (4):CD001945
3. Chong SA, Tan EC, Tan CH, Mythily, Chan YH: Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 116:51-54
4. Piette JD, Heisler M, Krein S, Kerr EA: The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005; 165:1749-1755
5. Day D: AIP: a proposed mechanism for evaluating adherence improvement initiatives. Adv Ther 2005; 22:87-95
6. Valdez CA, Ulrich H: Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. J Manag Care Pharm 2005; 11:499-504
7. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, Mountokalakis TD: Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12:243-249
8. Scott J, Pope M: Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63:384-390
9. Smith CM, Barzman D, Pristach CA: Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 1997; 37:147-154
10. Amadio PB, Cross LB, Amadio P Jr. New drugs for schizophrenia: an update for family physicians. Am Fam Physician 1997; 56:1149-1156, 1159-1160; correction, 1998; 57:40
11. Chabannes JP, Benattia I, Pascal JC, Azorin JM, Vidon G, Bouhassira M, Allicar MP: [What is the meaning of "stabilization" in schizophrenic patients?] Encephale 1998; 24:331-336 (French)
12. Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23:663-674
13. Chronic ambulatory outpatients and four-vector management. Am J Manag Care 1998; 4(suppl):S15-S19
14. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E: Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998; 39:215-219
15. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, Muller MJ: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26:156-160
16. Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T: Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci 1994; 19:254-264
17. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38
18. Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, Meyer FP: Therapeutic drug monitoring of clozapine and relapse - a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41:3-13
19. Raggi MA: Therapeutic drug monitoring: chemical-clinical correlations of atypical antipsychotic drugs. Curr Med Chem 2002; 9:1397-1409
20. Rao ML, Hiemke C, Grasmader K, Baumann P (TDM Arbeitsgruppe Der AGNP): [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring.] Fortschr Neurol Psychiatr 2001; 69:510-517 (German)
21. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, Muller MJ: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26:156-160
22. Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P: Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther 1995; 20:55-62
23. Hartung B, Wada M, Laux G, Leucht S: Perphenazine for schizophrenia. Cochrane Database Syst Rev 2005; (1):CD003443
24. Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, Rybakowski J, Bilikiewicz A, Bomba J, Debowska G: [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial]. Psychiatr Pol 2003; 37:641-655 (Polish)